NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology

Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company hopes...

      

Related Stories

• Natalizumab Fails In Stroke But A Phase III Study Of BIIB093 Beckons
• RSV Market: An Unmet Clinical Need For ReViral, And Big Pharma Too
• Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress

 

Original Article: NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology

More From BioPortfolio on "NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology"